This database contains 457 studies, archived under the term: "drug therapy"
Click here to filter this large number of results.
Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease
Galasko, D.,
Bell, J.,
Mancuso, J. Y.,
Kupiec, J. W.,
Sabbagh, M. N.,
van Dyck, C.,
Thomas, R. G.,
Aisen, P. S.
Objective: To examine safety, tolerability, and efficacy of PF-04494700, an inhibitor of the receptor for advanced glycation end products (RAGE), in mild to moderate Alzheimer disease (AD).; Methods: Double-blind, placebo-controlled trial at 40 academic centers (United States). Subjects with AD and Mini-Mental State Examination score 14-26 were randomized to PF-04494700 60 mg/day × 6 days, […]
Galantamine versus risperidone treatment of neuropsychiatric symptoms in patients with probable dementia: an open randomized trial
Freund-Levi, Yvonne,
Jedenius, Erik,
Tysen-Bäckström, Ann Christine,
Lärksäter, Marie,
Wahlund, Lars-Olof,
Eriksdotter, Maria
Objective: To examine the effects of galantamine and risperidone on neuropsychiatric symptoms in dementia (NPSD) and global function.; Methods: Using a randomized, controlled and open-blind, one-center trial at an in- and outpatient clinic at a university hospital, we studied 100 adults with probable dementia and NPSD. Participants received galantamine (N = 50, target dose 24 mg) […]
Is sertraline treatment or depression remission in depressed Alzheimer patients associated with improved caregiver well being? Depression in Alzheimer’s Disease Study 2
Flynn Longmire, Crystal V.,
Drye, Lea T.,
Frangakis, Constantine E.,
Martin, Barbara K.,
Meinert, Curtis L.,
Mintzer, Jacobo E.,
Munro, Cynthia A.,
Porsteinsson, Anton P.,
Rabins, Peter V.,
Rosenberg, Paul B.,
Schneider, Lon S.,
Weintraub, Daniel,
Lyketsos, Constantine G.
Objective: We wanted to assess if sertraline treatment (versus placebo) or remission of depression at 12 weeks (versus nonremission) in Alzheimer patients is associated with improved caregiver well being.; Methods: We conducted a randomized, double-blind, placebo-controlled clinical trial of the efficacy and safety of sertraline for the treatment of depression in individuals with Alzheimer disease […]
Oxytocin for frontotemporal dementia: A randomized dose-finding study of safety and tolerability
Finger, E. C.,
MacKinley, J.,
Blair, M.,
Oliver, L. D.,
Jesso, S.,
Tartaglia, M. C.,
Borrie, M.,
Wells, J.,
Dziobek, I.,
Pasternak, S.,
Mitchell, D. G. V.,
Rankin, K.,
Kertesz, A.,
Boxer, A.
Objective: To determine the safety and tolerability of 3 doses of intranasal oxytocin (Syntocinon; Novartis, Bern, Switzerland) administered to patients with frontotemporal dementia (FTD). Methods: We conducted a randomized, parallel-group, double-blind, placebo-controlled study using a dose-escalation design to test 3 clinically feasible doses of intranasal oxytocin (24, 48, or 72 IU) administered twice daily for […]
Comparing the efficacy and safety of Crocus sativus L. With memantine in patients with moderate to severe Alzheimer’s disease: A double‐blind randomized clinical trial
Farokhnia, Mehdi,
Shafiee Sabet, Mehdi,
Iranpour, Negar,
Gougol, Amirhossein,
Yekehtaz, Habibeh,
Alimardani, Roozbeh,
Farsad, Farzaneh,
Kamalipour, Maryam,
Akhondzadeh, Shahin
Objectives Limited pharmacological options are available for the management of Alzheimer’s disease (AD) in severe stages. Cognitive‐enhancing properties of saffron, the dried stigma of Crocus sativus L., have been evidenced in different studies. We aimed to compare the efficacy and safety of saffron extract versus memantine in reducing cognitive deterioration of patients with moderate to […]
Costs of dementia in Hungary
Érsek, K.,
Kovács, T.,
Wimo, A.,
Kárpati, K.,
Brodszky, V.,
Péntek, M.,
Jönsson, L.,
Gustavsson, A.,
McDaid, D.,
Kenigsberg, P. A.,
Valtonen, H.,
Gulácsi, L.
Objective: The main aim of this paper is to give an overview on the quality of life, health care utilisation and costs of dementia in Hungary.; Method: A cross-sectional non-population based study of 88 consecutive dementia patients and their caregivers was conducted in three GP practices and one outpatient setting in 2008. Resource Utilization in […]
Long-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized study
Emre, Murat,
Poewe, Werner,
De Deyn, Peter Paul,
Barone, Paolo,
Kulisevsky, Jaime,
Pourcher, Emmanuelle,
van Laar, Teus,
Storch, Alexander,
Micheli, Federico,
Burn, David,
Durif, Frank,
Pahwa, Rajesh,
Callegari, Francesca,
Tenenbaum, Nadia,
Strohmaier, Christine
Objective: This study investigated the long-term safety of rivastigmine (12 mg/d capsules, 9.5 mg/24 h patch) and effects on motor symptoms in patients with mild-to-moderately severe Parkinson disease dementia.; Methods: This was a 76-week, prospective, open-label, randomized study in patients aged 50 to 85 years. Primary outcomes included incidence of, and discontinuation due to, predefined […]
Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial
Dysken, Maurice W.,
Sano, Mary,
Asthana, Sanjay,
Vertrees, Julia E.,
Pallaki, Muralidhar,
Llorente, Maria,
Love, Susan,
Schellenberg, Gerard D.,
McCarten, J. Riley,
Malphurs, Julie,
Prieto, Susana,
Chen, Peijun,
Loreck, David J.,
Trapp, George,
Bakshi, Rajbir S.,
Mintzer, Jacobo E.,
Heidebrink, Judith L.,
Vidal-Cardona, Ana,
Arroyo, Lillian M.,
Cruz, Angel R.,
Zachariah, Sally,
Kowall, Neil W.,
Chopra, Mohit P.,
Craft, Suzanne,
Thielke, Stephen,
Turvey, Carolyn L.,
Woodman, Catherine,
Monnell, Kimberly A.,
Gordon, Kimberly,
Tomaska, Julie,
Segal, Yoav,
Peduzzi, Peter N.,
Guarino, Peter D.
Importance: Although vitamin E and memantine have been shown to have beneficial effects in moderately severe Alzheimer disease (AD), evidence is limited in mild to moderate AD.; Objective: To determine if vitamin E (alpha tocopherol), memantine, or both slow progression of mild to moderate AD in patients taking an acetylcholinesterase inhibitor.; Design, Setting, and Participants: […]